Omid Fakheran

Dr. Omid Fakheran

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
OFOmid Fakheran
Omid Fakheran
ZSZahra Saied-Moallemi
Zahra Saied-Moallemi
AKAbbasali Khademi
Abbasali Khademi
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Objective: High prevalence of Dental and periodontal problems during the gestation period may have a negative effect on oral health-related quality of life (OHRQoL) in pregnant women. This systematic review aimed to perform a quality assessment and provide a critical overview of the current research available on OHRQoL in pregnant women. Methods: For this systemic review, all original and peer-reviewed human studies, which investigated OHRQoL of women during pregnancy or post- partum period, were searched. Studies were screened in title and abstract for the relevance by two independent investigators. Methodological quality was assessed using modified items recommended by the Newcastle–Ottawa Scale for observational studies. Results: All of the eight included studies had a cross-sectional design. Meta-analysis was not possible due to the heterogeneity of key aspects among the included studies. Thus, the data from the studies were evaluated qualitatively. The overall risk of bias of the included studies was low. Conclusion: The main conclusion of this review is that the presence of signs and symptoms of dental and gingival disease negatively affects the self-perception of OHRQoL in pregnant women. The most affected domains of OHRQoL in pregnant women were related to mental and psychological discomfort, followed by physical and functional problems.

31 July 2020 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
PSPatrick R. Schmidlin
Patrick R. Schmidlin
AKAbbasali Khademi
Abbasali Khademi
OFOmid Fakheran
Omid Fakheran

17 August 2022 in Medicina Oral Patología Oral y Cirugia Bucal
Verified
Journal Article
Open access
PPP. Parhizkar
P. Parhizkar
PSPr. Schmidlin
Pr. Schmidlin
MBMm. Bornstein
Mm. Bornstein
OFOmid Fakheran
Omid Fakheran
Third molar surgery is frequently associated with postoperative discomfort such as pain, edema and trismus. We aimed to evaluate the current evidence on the efficacy of adjunctive corticosteroid therapy in improving patient-centered outcomes following third molar surgery. This systematic review assessed and searched PubMed, Google scholar, Scopus, web of science, clinicaltrials.gov and Cochrane central for controlled trials, up to May 2021. The primary outcome measures were patient-centered outcomes such as quality of life following the use of adjunctive corticosteroid therapy in third molar removal. Only randomized controlled trials published in English language were included. A total of 355 studies were initially identified, and 12 studies were finally included. The results showed that both methylprednisolone and dexamethasone decreased postoperative side effects such as pain, trismus, and edema and consequently were improving patient reported outcomes. In this regard, none of the included papers reported any significant statistical difference between these two drugs (p > 0.05). The analysis regarding the route of administration for the corticosteroids showed that local and intravenous injection of dexamethasone had equivalent effects, and both methods showed better results as compared to simple oral administration. Adjunctive use of corticosteroid drugs may improve patient-centered outcomes following third molar surgery. However, there is no significant difference between drugs and routs of administration. Comparing various administration routs, local submucosal injection of dexamethasone seems to be a straightforward, painless and cost-effective adjunctive therapy. Key words:Third molars, corticosteroids, patient-reported outcomes, health related quality of life.

20 March 2021 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
PSPatrick R. Schmidlin
Patrick R. Schmidlin
MDMandana Dehghannejad
Mandana Dehghannejad
OFOmid Fakheran
Omid Fakheran
Background: Interleukin (IL)-35 is a novel anti-inflammatory cytokine that is produced by regulatory T cells. IL-35 mediates immunological functions and plays a protective role in several diseases such as asthma and rheumatoid arthritis. However, the role of IL-35 in gingivitis and periodontitis remains unclear. The aim of this study was to systematically review the literature and collecting the available evidence regarding the role of IL-35 in pathogenesis of periodontal disease.Methods: A systematic search of electronic databases including MEDLINE, Google Scholar, Cochrane Library, Web of Science, and Scopus was conducted in November 2020 to identify studies addressing the Interleukin-35 pathobiology in periodontal disease. The identified studies were subjected to pre-identified inclusion criteria. The retrived papers were assessed by the authours independently and consensus was reached in cases where disagreement occurred. Articles written in languages other than English, case reports, letters to editors, conference abstracts, theses, and dissertations were excluded from the review.Results: A total of 176 possibly relevant articles were identified through the search strategy. Finally, 15 papers which met the criteria of eligibility were included in this review by consensus. The included articles were classified based on their design and level of evidence.Three subclinical study, ten cross sectional investigation and two randomized clinical trials constituted the final set of studies in this review. At preclinical level, Il-35 showed inhibitory characteristics regarding alveolar bone resorption of animal periodontitis models. The results of observatory human studies confirmed the presence of high levels of IL-35 in saliva, GCF, serum, and gingival biopsies of patients suffering from inflammatory periodontal disease. Moreover, two included clinical trials showed that non-surgical periodontal therapy could downregulate IL-35 production in chronic periodontitis patients.Conclusion: Interleukin-35 has an undeniable role in pathobiology of inflammatory periodontal disease. Further well-controlled studies are needed to better elucidate the functional pattern of IL-35 in pathogeneisis of gingival and periodontal disease.

3 June 2023 in Special Care in Dentistry
Verified
Journal Article
Open access
ACAkram Charoosaee
Akram Charoosaee
MDMandana Dehghannejad
Mandana Dehghannejad
OFOmid Fakheran
Omid Fakheran
LMLeonardo Marchini
Leonardo Marchini
Aims: A longer life and the growing population of older adults are the achievements of the 20th century. The World Health Organization considers ageism an important barrier to age‐appropriate care for older adults. The aim of this study was to translate and validate the ageism scale for dental students in Iran (ASDS‐Persian).Methods: The 27‐question ASDS was translated from English into Persian (Farsi) and completed by 275 dental students from two universities in Isfahan, Iran. Principal component analysis (PCA), internal consistency reliability, and discriminant validity were estimated. Furthermore, in this study we conducted an analytical cross sectional study among dental students of Isfahan province (two universities) with the aim of proving data regarding their ageism beliefs and attitudes.Results: PCA revealed an 18‐question, four‐component scale with acceptable validity and reliability. The four components are ‘barriers/concerns on dental treatment in older adults’, ‘opinions about older adults’, ‘practitioner's perspective,’ and ‘older adults’ perspective’.Conclusion: This preliminary validation of ASDS‐Persian produced a new 18‐question scale with four components with acceptable validity and reliability. This instrument could be further tested in larger samples in Farsi speaking countries.

14 January 2025 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
BABehrouz Arefnia
Behrouz Arefnia
OFOmid Fakheran
Omid Fakheran
NJNorbert Jakse
Norbert Jakse
MPMichael Payer
Michael Payer
Purpose: Zirconia dental implants show excellent biocompatibility and tissue integration, low affinity for plaque, and favorable biomechanical properties. However, these objective measures do not adequately replicate the patient’s perception. This systematic review evaluated the evidence on patient-reported outcome (PROs) in zirconia dental implant treatment. Methods: A systematic literature review was conducted following the PRISMA guidelines, utilizing six electronic databases, and supplemented by a manual search of relevant journals and websites to ensure a thorough and comprehensive screening process. The identified studies were subjected to preidentified inclusion criteria. Only controlled clinical trials published in English were considered without limitations on the year of publication. Data on the study characteristics (follow-up, survival rate (%), implant system, number of implants, and type of treatment), PROMs, level of evidence, and Methodological Index for Nonrandomized Studies (MINORS) Bias Score were extracted. Results: The initial database and hand search yielded 596 articles; 189 were included in the title and abstract screening after excluding the duplicates. Eighteen articles were selected based on the inclusion criteria, among which six were excluded because they did not match the research question. Thus, the final selection comprised 12 articles. Most PROMs (aesthetics, speaking, comfort, chewing ability, and general satisfaction) at prosthetic delivery revealed significantly improved average scores than those at pretreatment. Conclusions: Despite the respective limitations of the articles included in this systematic review, patients revealed high satisfaction levels with regard to zirconia dental implants. A high level of heterogeneity was observed among the instruments used for measuring the patient-reported outcomes in patients with zirconia implants, thus highlighting the need to develop specific PROMs in the future.